LONDON--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced both the launch of Dexcom ONE+, a CGM ...
The device is similar to existing prescription CGMs. Users pair the wearable sensor with an application, put it on their arm and receive a continuous stream of glucose data on their smartphone or ...
The FDA has cleared its first over-the-counter wearable blood sugar tracker, with Dexcom’s slimmed-down Stelo continuous glucose monitor. The agency’s green light allows adults 18 years and older who ...
Stelo will be the first glucose biosensor in the US cleared for use without a prescription Indicated for use for people 18 years and older who are not using insulin therapy A small, wearable sensor ...
Dexcom launched its first over-the-counter continuous glucose monitor called Stelo on Monday. Users can buy a one-month supply online for $99, or sign up for an ongoing subscription at $89 a month.
Tuesday, the FDA approved DexCom Inc’s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM). The Dexcom Stelo Glucose Biosensor System is ...
After months of international availability, the Dexcom G7 constant glucose monitor received its FDA clearance to distribute in the US. Ahead of the wide rollout, we got to go hands-on with a demo ...
Dexcom announced that its G7 diabetes sensor can now link directly to a user’s Apple Watch, allowing them to track their glucose readings in real-time even if their iPhone isn’t nearby. According to ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback